Motif Bio PLC Publication of circular and notice of GM (8875Q)

TIDMMTFB

RNS Number : 8875Q

Motif Bio PLC

05 December 2016

Motif Bio plc

("Motif Bio" or the "Company")

5 December 2016

PUBLICATION OF CIRCULAR AND NOTICE OF GENERAL MEETING

Motif Bio plc (AIM: MTFB), the clinical stage biopharmaceutical company specialising in developing novel antibiotics, announces that on Friday 2 December 2016 it sent to Shareholders a circular and notice of General Meeting to be held at the offices of Reed Smith LLP at The Broadgate Tower, 20 Primrose Street, London EC2A 2RS on 21 December 2016 at 2.00 p.m. at which the following Resolutions will be proposed:

(A) Resolution 1, which will be proposed as an ordinary resolution, is to authorise the Directors to allot relevant securities up to an aggregate nominal value of GBP313,938.23 in connection with the exercise of various share options, warrants and convertible securities granted by the Company between 1 April 2015 and the date of this document;

(B) Resolution 2, which will be proposed as an ordinary resolution, is to authorise the Directors to allot relevant securities otherwise than for the purposes set out in resolution 1 up to an aggregate nominal amount of GBP270,965.62;

(C) Resolution 3, which will be proposed as a special resolution and which is subject to the passing of resolution 1, is to disapply statutory pre-emption rights, provided that such authority shall be limited to, inter alia, the allotment of equity securities in connection with the exercise of various share options, warrants and convertible securities granted by the Company between 1 April 2015 and the date of this document; and

(D) Resolution 4, which will be proposed as a special resolution and which is subject to the passing of resolution 2, is to disapply statutory pre-emption rights, provided that such authority shall be limited to, inter alia, the allotment of equity securities otherwise than in connection with the purposes set out in resolution 1 up to an aggregate nominal amount of GBP270,965.62.

The circular together with notice of General Meeting, is available on the Company's website at www.motifbio.com. Capitalised terms used herein but not defined have the same meanings as set out in the circular.

For further information please contact:

 
 Motif Bio plc                                                   info@motifbio.com 
  Richard Morgan (Chairman) 
  Graham Lumsden (Chief 
  Executive Officer) 
 Zeus Capital Limited (NOMAD 
  & BROKER) 
  Phil Walker/Giles Balleny 
  Dominic Wilson                                               +44 (0)20 3829 5000 
 Northland Capital Partners 
  Limited (BROKER) 
  Patrick Claridge/ David 
  Hignell 
  John Howes/ Rob Rees (Broking)                               +44 (0)20 3861 6625 
 Walbrook PR Ltd. (FINANCIAL        +44 (0)20 7933 8780 or motifbio@walbrookpr.com 
  PR & IR)                                                Mob: +44 (0)7980 541 893 
  Paul McManus                                            Mob: +44 (0)7900 608 002 
  Mike Wort 
 
 MC Services AG (EUROPEAN 
  IR) 
 Raimund Gabriel                                                +49 (0)89 210 2280

About Motif Bio

Motif Bio is a clinical-stage biopharmaceutical company, engaged in the research and development of novel antibiotics designed to be effective against serious and life-threatening infections in hospitalised patients caused by multi-drug resistant bacteria. Our lead product candidate, iclaprim, is being developed for the treatment of acute bacterial skin and skin structure infections (ABSSSI) and hospital acquired bacterial pneumonia (HABP), including ventilator associated bacterial pneumonia (VABP), which is often caused by MRSA (methicillin resistant Staphylococcus aureus). We are currently enrolling and dosing patients in two global Phase 3 clinical trials (Revive 1 and Revive 2) with an intravenous formulation of iclaprim, for the treatment of ABSSSI. Data readout for REVIVE-1 is expected in the second quarter of 2017 and REVIVE-2 is on track for data readout in the second half of 2017.

This information is provided by RNS

The company news service from the London Stock Exchange

END

NOGFSMFMDFMSEEE

(END) Dow Jones Newswires

December 05, 2016 02:47 ET (07:47 GMT)

Grafico Azioni Motif Bio (LSE:MTFB)
Storico
Da Giu 2024 a Lug 2024